Nephrology
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
Conference Coverage
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
FDA/CDC
Terlipressin squeaks by FDA review for hepatorenal syndrome 1
The FDA advisory committee’s 8-7 vote favoring approval of terlipressin for hepatorenal syndrome type 1 reflected concerns and misgivings.
News
Where does dexamethasone fit in with diabetic ketoacidosis in COVID-19?
Author of new article discussing considerations around diabetic ketoacidosis in the setting of COVID-19 also speaks to the findings this week that...
News
Large COVID-19 dataset: Kidney injury in >35% of those in hospital
The clearest risk factors for the development of AKI were “the need for ventilator support or vasopressor drug treatment.”
FDA/CDC
Dapagliflozin trial in CKD halted because of high efficacy
An independent data monitoring committee recommended stopping the trial.
Reports From the Field
Improving Nephropathy Screening in Appalachian Patients With Diabetes Using Practice-Wide Outreach
Outcomes Research in Review
Cardioprotective Effect of Metformin in Patients with Decreased Renal Function
FDA/CDC
FDA approves cefiderocol for multidrug-resistant, complicated urinary tract infections
The approval is for patients with limited or no alternative treatment options and includes a warning of Fetroja’s higher all-cause mortality rate...
News
HCV+ kidney transplants: Similar outcomes to HCV- regardless of recipient serostatus